Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population

Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population

Effective vaccine coverage is urgently needed to tackle the COVID-19 pandemic. Inactivated vaccines have been introduced in many countries for emergency usage, but have only provided limited protection. Heterologous vaccination is a promising strategy to maximise vaccine immunogenicity. Here, we con...

Full description

Bibliographic Details
Main Authors: Porntip Intapiboon, Purilap Seepathomnarong, Jomkwan Ongarj, Smonrapat Surasombatpattana, Supattra Uppanisakorn, Surakameth Mahasirimongkol, Waritta Sawaengdee, Supaporn Phumiamorn, Sompong Sapsutthipas, Pasuree Sangsupawanich, Sarunyou Chusri, Nawamin Pinpathomrat
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Vaccines
Subjects:
intradermal
mRNA vaccine
inactivated SARS-CoV-2
COVID-19
immunogenicity
Online Access:https://www.mdpi.com/2076-393X/9/12/1375

Similar Items

Similar Items